Sanofi vaccine to enter Phase III of clinical trials

On 27 May 2021, the Sanofi laboratory announced the transition to large-scale trials of its Covid-19 vaccine. Phase III is used to evaluate the efficiency of the vaccine, which will be tested on 35 000 people in several countries, including the United States.

In a best-case scenario, Sanofi's vaccine could be marketed by the end of 2021, one year after the first Covid-19 vaccines became available.